Department of Gynaecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
Department of Laboratory Medicine, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
Pathol Res Pract. 2020 Feb;216(2):152794. doi: 10.1016/j.prp.2019.152794. Epub 2019 Dec 20.
To evaluate the correlation between expression of p53, Livin, Excision repair cross-complementation group 1 (ERCC1), BRCA1 and Poly (ADP-ribose) polymerase 1 (PARP 1) in epithelial ovarian cancer (EOC) tissues with platinum-based chemotherapy and prognosis in patients who received either comprehensive surgical staging or cytoreductive surgery.
The protein expressions level of five potential regulators involved in chemo-resistance, including p53, Livin, ERCC1, BRCA1 and PARP1 in EOC tissues from 66 patients were evaluated using immunohistochemistry method. We also measured preoperative CA125 level measured by an electrochemiluminescence immunoassay (ECLIA) in all patients. Cox proportional hazard regression model was established to identify whether these proteins are associated with overall survival.
Chemo-resistance and poor overall survival were shown to be significantly related with positive expressions of p53, Livin, ERCC1, BRCA1 and PARP1. The evaluation of risk factors on the chemo-resistance showed that ERCC1 and BRCA1 are strong risk factors (OR: 21.12 and 21.61, all P < 0.01), while the positive expression of ERCC1, BRCA1 and PARP1 was significantly highly associated with the overall survival (HR: 3.9, 3.7 and 2.6, all P < 0.05, respectively). CA125 levels were significantly higher in patients with positive expression of P53, BRCA1, ERCC1 or Livin compared with those with negative expression (471:146, 667:260, 494:261 and 4589:89 U/ml, respectively, all P < 0.05).
The elevated expression levels of ERCC1 and BRCA1 were identified as significant risk factors for chemo-resistance in EOC. Reduced expression levels of ERCC1, BRCA1 and PARP1 were significantly associated with better overall survival. The CA125 levels were significantly higher in patients with EOC specimens that were positive of p53, BRCA1, ERCC1 and Livin.
评估上皮性卵巢癌(EOC)组织中 p53、Livin、切除修复交叉互补基因 1(ERCC1)、BRCA1 和多聚(ADP-核糖)聚合酶 1(PARP1)的表达与接受全面手术分期或细胞减灭术的患者铂类化疗的相关性和预后。
采用免疫组织化学法检测 66 例 EOC 组织中 5 种潜在化疗耐药调节剂(p53、Livin、ERCC1、BRCA1 和 PARP1)的蛋白表达水平,并用电化学发光免疫分析法(ECLIA)测量所有患者术前 CA125 水平。采用 Cox 比例风险回归模型确定这些蛋白是否与总生存相关。
化疗耐药和总体生存不良与 p53、Livin、ERCC1、BRCA1 和 PARP1 的阳性表达显著相关。对化疗耐药的危险因素评估显示,ERCC1 和 BRCA1 是强危险因素(OR:21.12 和 21.61,均 P < 0.01),而 ERCC1、BRCA1 和 PARP1 的阳性表达与总生存显著相关(HR:3.9、3.7 和 2.6,均 P < 0.05)。与阴性表达相比,p53、BRCA1、ERCC1 或 Livin 阳性表达的患者 CA125 水平显著升高(471:146、667:260、494:261 和 4589:89 U/ml,均 P < 0.05)。
EOC 中 ERCC1 和 BRCA1 表达水平升高被认为是化疗耐药的显著危险因素。ERCC1、BRCA1 和 PARP1 表达水平降低与总生存显著相关。p53、BRCA1、ERCC1 和 Livin 阳性的 EOC 标本患者 CA125 水平显著升高。